{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT05756569","nct_id":"NCT05756569","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05756569. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive enfortumab vedotin IV and pembrolizumab IV on study. Patients also undergo CT scan or MRI, and collection of blood throughout the trial.","label":"Treatment (enfortumab vedotin, pembrolizumab)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)","Seagen Inc.","Astellas Pharma Inc","Merck Sharp & Dohme LLC"],"completion_date":{"date":"2027-12-16","type":"ESTIMATED"},"conditions":["Bladder Squamous Cell Carcinoma","Locally Advanced Bladder Carcinoma","Malignant Renal Pelvis Neoplasm","Malignant Ureter Neoplasm","Malignant Urethral Neoplasm","Metastatic Bladder Carcinoma","Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Unresectable Bladder Carcinoma","Urachal Adenocarcinoma","Bladder Adenocarcinoma"],"enrollment":{"count":25,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"],"type":"PROCEDURE"},{"name":"Computed Tomography","otherNames":["CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized Tomography","CT","CT Scan","tomography"],"type":"PROCEDURE"},{"name":"Enfortumab Vedotin","otherNames":["AGS 22ME","AGS-22M6E","Anti-Nectin 4 ADC ASG-22CE","Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E","ASG-22CE","Enfortumab Vedotin-ejfv","Padcev"],"type":"DRUG"},{"name":"Magnetic Resonance Imaging","otherNames":["Magnetic Resonance","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging"],"type":"PROCEDURE"},{"name":"Pembrolizumab","otherNames":["Keytruda","Lambrolizumab","MK-3475","SCH 900475"],"type":"BIOLOGICAL"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-07-29","lead_sponsor":"Emory University","official_title":"Phase II Single-Arm Study of Enfortumab Vedotin (EV) Plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-12-16","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate","timeFrame":"Up to 2 years"}],"references":[],"start_date":{"date":"2023-09-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology","url":"https://clinicaltrials.gov/study/NCT05756569"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05756569"}